Table 1 Baseline characteristics of the enrolled patients in the study

Total number of the enrolled patients

20 (100)

Age at diagnosis, Median (range), years-old

48 (45–68)

FIGO Staging Classification

 I

 II

 III

 Unknow

1 (5.0)

4 (20.0)

13 (65.0)

2 (10.0)

Tumor histology

 Serous

 Others

17 (85.0)

3 (15.0)

Neoadjuvant treatment

 Yes (PTX plus CBP)

 No

7 (35.0)

13 (65.0)

Targeted molecular therapy (Olaparib)

 Olaparib

 No

5 (25.0)

15 (75.0)

First-line chemotherapy

 PTX plus CBP

 PTX plus DDP

13 (65.0)

3 (15.0)

 Other platinum-containing regimens

4 (20.0)

Operation interval, Median (range), months

29.5 (13.5–60.0)

Platinum-free interval (PFI), Median (range), months

15.0 (6.0-36.5)

Follow-up, Median (range), months

 Live

 Death

 Lose

63.0 (34.0-108.0)

12 (60.0)

7 (35.0)

1 (5.0)